Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Sana Biotechnology (SANA)

Sana Biotechnology Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SANA
DateTimeSourceHeadlineSymbolCompany
08/01/202521:05GlobeNewswire Inc.Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SANASana Biotechnology Inc
07/01/202521:05GlobeNewswire Inc.Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without ImmunosuppressionNASDAQ:SANASana Biotechnology Inc
16/12/202421:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SANASana Biotechnology Inc
02/12/202414:00GlobeNewswire Inc.Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus ErythematosusNASDAQ:SANASana Biotechnology Inc
26/11/202423:20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SANASana Biotechnology Inc
25/11/202422:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SANASana Biotechnology Inc
25/11/202421:05GlobeNewswire Inc.Sana Biotechnology to Present at December 2024 Investor ConferencesNASDAQ:SANASana Biotechnology Inc
08/11/202414:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SANASana Biotechnology Inc
08/11/202414:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
08/11/202414:00GlobeNewswire Inc.Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
04/11/202421:30GlobeNewswire Inc.Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025NASDAQ:SANASana Biotechnology Inc
23/10/202412:00PR Newswire (US)Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering IntelligenceNASDAQ:SANASana Biotechnology Inc
21/10/202421:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SANASana Biotechnology Inc
08/10/202420:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
03/10/202412:00PR Newswire (US)Invaio Sciences Appoints André Andonian as Chairman of the Board of DirectorsNASDAQ:SANASana Biotechnology Inc
30/09/202420:05GlobeNewswire Inc.Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day ConferenceNASDAQ:SANASana Biotechnology Inc
12/09/202420:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
29/08/202420:05GlobeNewswire Inc.Sana Biotechnology to Present at September 2024 Investor ConferencesNASDAQ:SANASana Biotechnology Inc
26/08/202420:05GlobeNewswire Inc.Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific OfficerNASDAQ:SANASana Biotechnology Inc
08/08/202420:21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SANASana Biotechnology Inc
08/08/202420:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
08/08/202420:05GlobeNewswire Inc.Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
06/08/202410:30PR Newswire (US)Flagship Pioneering Announces Appointment of Raj Panjabi as Senior PartnerNASDAQ:SANASana Biotechnology Inc
15/07/202420:12Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:SANASana Biotechnology Inc
07/06/202420:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SANASana Biotechnology Inc
07/06/202420:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
21/05/202413:00GlobeNewswire Inc.Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other GliaNASDAQ:SANASana Biotechnology Inc
08/05/202420:49Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SANASana Biotechnology Inc
08/05/202420:21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SANASana Biotechnology Inc
08/05/202420:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
 Showing the most relevant articles for your search:NASDAQ:SANA